Chinese Japanese Germany Korea


Description Treatment for Early-stage Breast Cancer Uses Pharmacokinetics Indications and Usage Clinical Research
Anastrozole structure
Chemical Name:
Molecular Formula:
Formula Weight:
MOL File:

Anastrozole Properties

Melting point:
Boiling point:
469.7±55.0 °C(Predicted)
1.08±0.1 g/cm3(Predicted)
storage temp. 
room temp
DMSO: soluble40mg/mL
CAS DataBase Reference
120511-73-1(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
anastrozole; Arimidex
NCI Drug Dictionary
ATC code
  • Risk and Safety Statements
Signal word  Danger
Hazard statements  H302-H360
Precautionary statements  P201-P301+P312+P330-P308+P313-P280
Hazard Codes  Xi,Xn
Risk Statements  36/37/38-22-61-60
Safety Statements  26-37/39
RIDADR  3249
WGK Germany  3
RTECS  CZ1465000
HazardClass  6.1(b)
PackingGroup  III
HS Code  29339980

Anastrozole price More Price(9)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich A2736 Anastrozole ≥98% (HPLC) 120511-73-1 10mg $88.2 2021-03-22 Buy
Sigma-Aldrich Y0001522 Anastrozole European Pharmacopoeia (EP) Reference Standard 120511-73-1 $190 2021-03-22 Buy
Sigma-Aldrich 1034807 Anastrozole 120511-73-1 200mg $589 2021-03-22 Buy
Cayman Chemical 11987 Anastrozole ≥98% 120511-73-1 50mg $99 2021-03-22 Buy
Cayman Chemical 11987 Anastrozole ≥98% 120511-73-1 10mg $45 2021-03-22 Buy

Anastrozole Chemical Properties,Uses,Production


Anastrozole, chemically known as 2,2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropiononitrile) a derivative of benzotriazole with the CAS registry number 120511-73-1, is a non-steroidal, third-generation achiral triazole derivative marketed as ARIMIDEX® by AstraZeneca Pharmaceuticals LP1. It is one of the third-generation aromatase inhibitor which is a highly competitive and selective inhibitor of aromatase, thus blocking the conversion of testosterone into estradiol and androstenedione into estrone. Inhibition of the aromatase enzyme occurs particularly through competitive binding of aromatase to the hemegroup of cytochrome P450, decreasing estrogen biosynthesis in the peripheral tissues of the body and in the breast.

Treatment for Early-stage Breast Cancer

Anastrozole is a generally well tolerated treatment for early-stage breast cancer. Like other aromatase inhibitors, its most important adverse effect was an increased risk of bone fractures, which for anastrozole was restricted to the treatment period. It characteristically has mild toxicity when compared with chemotherapy; however, it have been noticed that more patients treated with anastrozole have complained of joint symptoms than expected, particularly digital stiffness similar to that of rheumatoid arthritis. Some clinical trials of anastrozole for postmenopausal women with breast cancer in Europe and the United states reported musculoskeletal disorders as adverse events.
Anastrozole (Arimidex®) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer. It is also approved in the EU and other countries worldwide for continuing adjuvant treatment in women who have already had 2–3 years of adjuvant tamoxifen treatment for breast cancer.


Anastrozole has significant effects on breast cancer treatment and, therefore, it is currently used as first-line treatment in estrogen receptor (ER)-positive postmenopausal women, particularly to treat locally advanced or metastatic breast cancer. Furthermore, it is also indicated for early cancer treatment, tumor chemoprevention and postmenopausal women using tamoxifen, especially if the drug is used during a prolonged period of time and has been indicated in the disease’s recurrence, i.e., as another therapeutic endocrine option.


Anastrozole has linear pharmacokinetics. It is metabolized primarily in the liver, with a plasma elimination half-life of 40–50 hours, indicating that oncedaily administration is adequate. In vitro and clinical studies indicate that drugdrug interactions are unlikely to occur between anastrozole and drugs metabolized by hepatic cytochrome P450 enzymes. In patients with breast cancer, there were no clinically important interactions between anastrozole and tamoxifen or its metabolite, N-desmethyltamoxifen.

Indications and Usage

Anastrozole is a potent selective triazole aromatase inhibitor that inhibits the aromatase that cytochrome P-450 is dependent on to prevent the biosynthesis of estrogen. Estrogen is the main stimulating factor for breast cancer cell growth. This drug’s half maximal inhibitory concentration (IC50) value to human placental aromatase is 15nmol/L. Compared to the traditional drug tamoxifen, Anastrozole can comprehensively and effectively lower the risks of breast cancer recurrence and metastasis, thus extending patients’ disease-free survival.
Anastrozole is suitable for treating postmenopausal advanced breast cancer patients, especially postmenopausal advanced breast cancer patients who experienced recurrence following hormone assisted therapy.

Clinical Research

A series of clinical trials compared the effects of third generation aromatase inhibitor Anastrozole with those of tamoxifen. The trial was a global multicenter trial and includes 381 centers in 21 countries. Since 1996, there have been 9366 patients who have participated, and the follow-up time is 100 months. 25.8% of patients in the Anastrozole group experienced recurrence, while 29.9% of patients in the tamoxifen group did. Thus, Anastrozole’s recurrence rate was 4.1% lower than that of tamoxifen, and its risk of distant metastasis was lower as well. Anastrozole is also safer than tamoxifen.


Anastrozole entered its first market in the United Kingdom for the treatment of advanced breast cancer in post-menopausal women. Anastrozole is a highly potent and selective aromatase inhibitor. It is extremely potent in lowering circulating estradiol to undetectable levels in treated patients without altering other circulating hormones. The drug is reportedly well absorbed and tolerated following oral administration.

Chemical Properties

Crystalline Solid


Zeneca (United Kingdom)


antiseptic, spermaticide


An aromatase inhibitor. Used as an antineoplastic.


ChEBI: A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position.

Manufacturing Process

A mixture of 2,2-(5-methyl-1,3-phenylene)di(2-methylpropionitrile) (2.26 g), N-bromosuccinimide (1.78 g), benzoylperoxide (0.05 g) and carbon tetrachloride (50 ml) was refluxed for 2 hours, cooled and filtered, and the filtrate was evaporated to dryness under reduced pressure. The residue was dissolved in dimethylformamide (20 ml), sodium triazole (1.8 g) was added, and the mixture was stirred at room temperature for 18 h. Water (100 ml) was added, and the mixture was extracted twice with ethyl acetate, dried and evaporated to dryness and the residue was purified by flash column chromatography, eluting with ethyl acetate to give 2,2-[5-(1H-1,2,4-triazol-1- ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), mp 81-82°C after crystallization from ethyl acetate/cyclohexane.
The 5-methyl-1,3-phenylene compound used as starting material in above process may be prepared as follows. The mixture of 3,5- bis(bromomethyl)toluene (30 g), tetrabutyl-ammonium bromide (1 g), KCN (17.6 g), dichloromethane (100 ml) and water (30 ml) was stirred vigorously and refluxed for 3 h. The mixture was cooled, diluted with water (100 ml) and extracted three times with ethyl acetate, dried and evaporated to dryness, the residue was purified by flash chromatography, eluting with petroleum ether/ethyl acetate (3:1) to give 2,2-(5-methyl-1,3-phenylene)diacetonitrile, mp 73-74°C after crystallization from carbon tetrachloride. A mixture of this diacetonitrile (11.5 g), iodomethane (42 g) and dimethylformamide (150 ml) was cooled in an ice and stirred while sodium hydride (50% dispersion in mineral oil, 15 g) was added slowly, over 1 hour, then the mixture was allowed to warm to room temperature, stirred for 2 h, 500 ml of water was added, and the mixture was extracted twice with ethyl acetate, the extracts were dried and evaporated to dryness and the residue was crystallized from carbon tetrachloride to give the required 5-methyl-1,3-phenylene starting material, mp 126-127°C.

brand name

Arimidex (AstraZeneca).

Therapeutic Function


General Description

Anastrozole,α,α,α',α'-tetramethyl5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile,was the first specific aromatase inhibitor approved in theUnited States. It is indicated for first-line treatment of postmenopausalwomen with advanced or metastatic breast cancer,for second-line treatment of postmenopausal patientswith advanced breast cancer who have had disease progressionfollowing tamoxifen therapy, and for adjuvant treatmentof women with early breast cancer. Patients who did not respondto tamoxifen therapy rarely respond to anastrozole.

Biological Activity

Potent and highly selective aromatase (CYP19) inhibitor (IC 50 = 15nM) that has no discernible effect on adrenocorticoid hormone synthesis. Reduces plasma estrogen levels and exhibits antitumor activity in vivo . Orally active.

Mechanism of action

Anastrozole, a benzyltriazole derivative, competes with the natural s ubstrate for binding to the active site of the aromatase. The mechanism of enzyme inhibition resides in the coordination of the triazole ring with the hemeiron atom of the aromatase enzyme complex. This coordination ultimately prevents arom atization of androgens into estrogens and, therefore, deprives the tumor of estrogen. This effect is reversible. In the presence of anastrozole, estradiol levels are reduced to undetectable levels, with no adverse effects on levels of any other horm one, including cortisol and aldosterone.


Anastrozole is well absorbed orally, with biliary elimination as its primary route (85%) and an elimination half-life of approxim ately 50 hours. Approximately 60% of an oral dose is m etabolized in the liver by N-dealkylation, hydroxylation, and glucuronidation to inactive triazole metabolites.

Clinical Use

Anastrozole is a potent and highly selective, nonsteroidal aromatase inhibitor utilized in the treatment of advanced breast cancer that is horm one-responsive. It is considered to be second-line therapy (after tamoxifen) in the treatment of postm enopaus al breast cancer.

Anastrozole Preparation Products And Raw materials

Raw materials

Preparation Products

Anastrozole Suppliers

Global( 453)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
18007166089 86-18007166089 CHINA 230 58
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-34979012 CHINA 739 60
hdzhl biotechnology co., ltd
86-13032617415 CHINA 1275 58
Hebei Bonster Technology Co.,Limited
0086-13315996897 CHINA 998 58
15377521700 +8615377521700
027-81302088 CHINA 869 58
15327141851 027-81302090
027-81302088 CHINA 280 58
Qingdao kaimoshi biochemical technology co., ltd.
+(86) 571 87700752
+(86) 571 87700752 CHINA 145 58
Wuhan Fortuna Chemical Co., Ltd
86-27-59524646 CHINA 2944 58
Zhuozhou Wenxi import and Export Co., Ltd
+8613111626072 (WhatsApp)
Wechat: +8613111626072 Wickr me: waynehu CHINA 13187 58
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 China 20012 60

Related articles

View Lastest Price from Anastrozole manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-11-30 Anastrozole
US $100.00-10.00 / KG/CTN 1KG 99% 1000kg/month Shanxi Lianxu New Material Co., LTD
2021-11-30 Anastrozole (Arimidex)
US $1.00 / g 1000g 99% 20ton/month Wuhan Aoliqisi New Material Technology Co., Ltd.
2021-11-30 Anastrozole
US $80.00 / g/Bag 1g 99 100kg Baoji Guokang Bio-Technology Co., Ltd.

120511-73-1(Anastrozole)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved